Quantum BioPharma (NASDAQ: QNTM) is making strides in the development of a novel therapy for multiple sclerosis (MS), as highlighted in a recent article covering the company's progress. The therapy, known as LUCID-MS, is designed to address demyelination—the loss of the protective myelin sheath around nerve fibers—and aims to protect or restore myelin integrity. This approach could represent a significant shift in MS treatment, which traditionally relies on immune modulation rather than direct neural repair.
The company reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile, with the therapy generally well tolerated. These results support advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. The company believes the therapy may offer a differentiated, potentially first-in-class approach because it directly targets myelin loss and neurodegeneration, rather than solely modulating the immune system.
To strengthen operational support for the program, Quantum BioPharma is planning a partnership with Allucent and engaging with neurological specialists. This collaboration is expected to enhance the design and execution of the upcoming Phase 2 trial. The company's wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The broader implications of this advancement are substantial for the MS community, which currently lacks therapies that directly promote myelin repair. If successful, LUCID-MS could become a cornerstone treatment for multiple sclerosis, addressing the underlying neurodegeneration that leads to disability progression. For the biopharmaceutical industry, this represents a move toward regenerative therapies for neurodegenerative diseases, potentially opening new avenues for drug development.
Quantum BioPharma is also involved in other ventures, including an over-the-counter product called unbuzzd, which it invented and spun out to Unbuzzd Wellness Inc. The company retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. However, the company retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
For more details on the original article, visit https://ibn.fm/AUhNl. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
